HEMACARE CORP /CA/

HEMACARE CORP /CA/ insiders are currently net buyers of HEMA stock, showing bullish sentiment over the past 90 days. Executives have purchased $1.1M while selling $426.3K, resulting in a positive net flow of $706.6K. This buying activity represents 73% of total transaction volume.

HEMACARE CORP /CA/ has 7 active insiders who have filed SEC Form 4 transactions in the past 90 days. Capital Management Llc Praetorian (Executive) leads with 15 transactions totaling $1.3M. Der Tuuk Terry Van (Executive) follows with 5 transactions worth $158.3K. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.

The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. HEMACARE CORP /CA/'s current score of 73/100 indicates bullish insider sentiment. Scores above 60 suggest insiders are accumulating shares faster than selling, reflecting $1.1M in purchases versus $426.3K in sales.

The most recent insider transaction occurred on Sep 15, 2011, when Tuuk Terry Van Der (Executive) acquired 100,000 shares at $0.28 per share for $28.0K. This appears to be a discretionary trade.

Based on SEC Form 4 filings from the past 90 days, HEMA insider trading sentiment is currently bullish with an Alignment Score of 73/100. The net insider flow of $706.6K reflects accumulation, with 73% of volume being purchases.

SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like HEMACARE CORP /CA/. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At HEMA, we track all Form 4 filings—currently showing 25 transactions from 7 insiders over 90 days.

A 10b5-1 plan allows HEMACARE CORP /CA/ executives to pre-schedule stock sales when they don't possess material non-public information. At HEMA, approximately 0% of recent transactions are 10b5-1 trades. Most trading activity at HEMA appears discretionary, making insider signals more meaningful.

You can monitor HEMACARE CORP /CA/ (HEMA) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 7 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.

Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. HEMACARE CORP /CA/'s current score of 73/100 indicates strong bullish sentiment with executives accumulating shares. This is calculated from $1.1M in purchases versus $426.3K in sales over 90 days, resulting in a net flow of $706.6K.

SEC Form 4 filings are mandatory reports that HEMACARE CORP /CA/ insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At HEMA, the most common type is "P" with 14 occurrences. The most recent Form 4 was filed on Sep 15, 2011 by Tuuk Terry Van Der.

Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At HEMACARE CORP /CA/, approximately 0% of recent transactions are executed under 10b5-1 plans, while 100% appear to be discretionary trades. The low percentage means most insider activity at HEMA represents discretionary decisions with more informational value.